Navigation Links
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"We are thrilled to have reached the halfway point for enrollment in our GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "Once complete, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved patient outcomes. We continue our commitment to ensuring that the VerifyNow System is shown to be an integral tool in optimizing the use of antiplatelet therapy."


The concept of variability in response to antiplatelet therapy has been well established. Also being demonstrated with increased frequency is the question of whether poor response to antiplatelet therapy, based on a laboratory test, leads to poor patient outcomes. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company's VerifyNow System and P2Y12 Test reduces major cardiovascular adverse events post-PCI. The trial is being coordinated by Scripps Advanced Clinical Trials.

About Accumetrics (

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including EC-cleared product for prasugrel and FDA-cleared products for aspirin, Plavix, ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis.

    Jules Abraham
    Lippert/Heilshorn & Associates

    Timothy I. Still
    President and CEO

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
4. Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare Reform
5. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
6. Spherix Announces Positive Phase 2 Study Results
7. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
8. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
9. CoAxia, Inc. Announces $21.5M Series D Financing
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... , Oct. 13, 2015  Measurement in accountable ... and balancing financial incentives, but gaps in measurement ... care and health systems. A new, peer-reviewed ... Managed Care explores measurement gaps for ... sets. --> --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... Sir Grout of Greater Boston donated an expansive, seven room ... House Charities® (RMHC®). This donation was made in an effort to give back to ... inception. , “We believe strongly in the Ronald McDonald House Charities, and they are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware ... , ENGAGE delivers innovative health programs and interventions via mobile devices that provide ...
(Date:10/13/2015)... ... October 13, 2015 , ... Element ... products, introduced a new company, RightSensor™ LLC, an Internet of Things (IoT) hardware ... RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for critical data ...
(Date:10/13/2015)... ... , ... NavaFit Inc. today announced the launch of its NavaFit app for ... local fitness & sporting events, and stay motivated. Users can download the ... us to get more serious about fitness and wellness, individuals are constantly looking for ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
Breaking Medicine News(10 mins):